financetom
Business
financetom
/
Business
/
Graphite One Selects Ohio's "Voltage Valley" For Graphite Anode Material Manufacturing Plant
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Graphite One Selects Ohio's "Voltage Valley" For Graphite Anode Material Manufacturing Plant
Mar 20, 2024 10:24 AM

12:47 PM EDT, 03/20/2024 (MT Newswires) -- Graphite One Inc. ( GPHOF ) , planning a complete domestic U.S. supply chain for advanced graphite materials, announced Wednesday that its subsidiary, Graphite One (Alaska), Inc. (G1 AK) has selected Ohio's "Voltage Valley" as the site of the company's graphite anode manufacturing plant by entering into a land lease agreement for a 50 year term and an option to purchase, as more fully described herein.

The site, located in Niles, Ohio, is a brownfield site previously used for storage of national defense stockpile critical minerals by the U.S. government, and has been processed through Ohio's Environmental Protection Agency (EPA) Voluntary Action Program.

Anthony Huston, President and CEO of G1, said in a statement: "Ohio is the perfect home for the second link in our strategy to build a 100% U.S.-based advanced graphite supply chain - from mining to refining to recycling. The U.S, simply cannot maintain a 21st Century tech-driven economy without critical minerals like graphite."

The site is located in the heart of the automobile industry, in an area with ample low-cost electricity produced from renewable energy sources. It is accessible by road and rail, with nearby barging facilities. The site's existing power lines are sufficient for Graphite One's ( GPHOF ) Phase 1 production target of 25,000 tons per year (tpy) of battery-ready anode material, and land is available for follow-on phases to ramp to 100,000 tpy of production.

Water supply is also sufficient to support expanded operations.

It is anticipated that G1 AK's Ohio facility will manufacture synthetic graphite anode active materials. Production of natural graphite anode active materials will be added as soon as feedstock from G1 AK's Graphite Creek Project near Nome, Alaska is available.

Price: 0.93, Change: +0.01, Percent Change: +1.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Mbx Biosciences Prices Its IPO Of 10.2 Mln Shares At $16.00 Per Share
BRIEF-Mbx Biosciences Prices Its IPO Of 10.2 Mln Shares At $16.00 Per Share
Sep 13, 2024
Sept 12 (Reuters) - * MBX BIOSCIENCES ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING * MBX BIOSCIENCES - PRICING OF ITS IPO OF 10,200,000 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $16.00 PER SHARE Source text for Eikon: ...
US FDA approves injectable version of Roche's multiple sclerosis therapy
US FDA approves injectable version of Roche's multiple sclerosis therapy
Sep 13, 2024
Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple sclerosis. (Reporting by Urvi Dugar; Editing by Subhranshu Sahu) ...
FAA administrator to testify before Senate panel on Boeing oversight
FAA administrator to testify before Senate panel on Boeing oversight
Sep 13, 2024
WASHINGTON, Sept 12 (Reuters) - The head of the Federal Aviation Administration will testify on Sept. 25 before the Senate Permanent Subcommittee on Investigations on the planemaker's oversight of Boeing ( BA ), a committee aide told Reuters. The committee, led by Senator Richard Blumenthal, in June sharply questioned then Boeing ( BA ) CEO Dave Calhoun on the planemaker's...
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences raises $163.2 mln in US IPO
Sep 13, 2024
Sept 12 (Reuters) - MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering. The biotechnology company priced its offering of 10.2 million shares at $16 apiece, at the high-end of its targeted range of $14 to $16 each....
Copyright 2023-2026 - www.financetom.com All Rights Reserved